Efficacy of once weekly teriparatide in patients with glucocorticoid-induced osteoporosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Teriparatide (Primary) ; Alendronic acid
- Indications Osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms TOWER-GO
- 04 Jan 2017 Planned number of patients changed from 400 to 204.
- 04 Jan 2017 Planned End Date changed from 31 Jul 2017 to 31 Jul 2018.
- 04 Jan 2017 Status changed from recruiting to active, no longer recruiting.